L3VLUP
ProSign in

BIO · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BIOLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BIO
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBIOLLY
Q3 202017 holders, $1.7bn33 holders, $14.1bn
Q4 202013 holders, $2.2bn29 holders, $17.3bn
Q1 202115 holders, $2.2bn24 holders, $23.0bn
Q2 202118 holders, $2.7bn24 holders, $27.8bn
Q3 202116 holders, $3.5bn31 holders, $29.9bn
Q4 202119 holders, $3.3bn31 holders, $34.7bn
Q1 202222 holders, $2.4bn24 holders, $35.3bn
Q2 202215 holders, $1.2bn33 holders, $42.7bn
Q3 202217 holders, $857m31 holders, $43.4bn
Q4 202216 holders, $782m31 holders, $46.6bn
Q1 202311 holders, $833m33 holders, $44.3bn
Q2 202316 holders, $607m37 holders, $59.6bn
Q3 202315 holders, $662m44 holders, $67.6bn
Q4 202311 holders, $534m45 holders, $73.6bn
Q1 20247 holders, $342m41 holders, $95.3bn
Q2 20246 holders, $409m43 holders, $110bn
Q3 20249 holders, $708m45 holders, $107bn
Q4 202411 holders, $649m46 holders, $93.9bn
Q1 202510 holders, $612m42 holders, $98.4bn
Q2 20258 holders, $780m43 holders, $93.2bn
Q3 20258 holders, $983m39 holders, $86.7bn
Q4 20259 holders, $1.2bn41 holders, $123bn
Q1 20268 holders, $1.2bn39 holders, $106bn
Q2 20267 holders, $1.1bn44 holders, $132bn
BIO

Bio Rad Labs Inc

Holders
8
Reported value
$983m
Buyers
4
Sellers
3

Breadth +1 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BIO (4)

ExodusPoint Capital Management LP, First Eagle Investment Management LLC, Moore Capital Management LP, Southeastern Asset Management Inc

Only LLY (35)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, and 10 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →